Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

Shares of Mineralys Therapeutics (MLYS) have recently gained 2% to $14.52, with Wall Street analysts projecting a mean price target of $36.25, indicating a potential 149.7% upside. While analyst price targets are often viewed skeptically due to inherent biases, the article emphasizes that a more compelling indicator for MLYS is the strong consensus among analysts for upward earnings estimate revisions, with the Zacks Consensus Estimate rising 10.2% over the past 30 days. This positive trend in earnings revisions, supported by a Zacks Rank #2 (Buy), suggests a legitimate basis for potential near-term stock appreciation.

Analysis

Mineralys Therapeutics, Inc. (MLYS) presents a compelling case based on analyst sentiment, though the signals require careful interpretation. While the mean price target of $36.25 from eight analysts suggests a potential 149.7% upside from the recent closing price of $14.52, the high standard deviation of $11.25 and wide target range ($15.00 to $48.00) indicate significant divergence in valuation perspectives. The more substantive bullish indicator is the positive trend in earnings estimate revisions. Over the last 30 days, four analysts have revised current-year EPS estimates higher with no negative revisions, causing the Zacks Consensus Estimate to increase by 10.2%. This upward revision trend is cited as a historically strong predictor of near-term stock performance and is the basis for the stock's Zacks Rank #2 (Buy), which is positioned as a more conclusive signal than the speculative price targets.

Key Decisions for Investors

• Investors should prioritize the positive trend in earnings estimate revisions over the highly speculative mean price target, as the 10.2% increase in the consensus estimate provides a more fundamentally grounded reason for a bullish outlook.
• The significant disagreement among analysts, reflected by the high standard deviation in price targets, signals a potential for high volatility, warranting careful position sizing and risk management.
• Given the Zacks Rank #2 (Buy) and upward earnings revisions, initiating or adding to a position could be considered, but it is crucial to monitor for continued positive revisions in subsequent periods to confirm the thesis.